The race is on to release the first proteomics-based ovarian cancer diagnostic: This week, Ciphergen announced that it hopes to translate a collaborative ovarian cancer study into a commercial assay “by year-end.” Meanwhile, at last week’s IBC Biomarker conference, Lance Liotta of the NCI-FDA clinical proteomics program announced that his group — which he co-directs with Emanuel Petricoin — is “now gathering patients” for a blinded clinical trial that compares the predictability of protein patterns to CA125 for ovarian cancer recurrence.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.